BIOMAT Database Logo BIOMAT Database Logo

Alterations of plasma immunoreactive glucagon-like peptide-1 behavior in non-insulin-dependent diabetics. 1990

M Hirota, and M Hashimoto, and M Hiratsuka, and C Ohboshi, and S Yoshimoto, and M Yano, and A Mizuno, and K Shima
Department of Laboratory Medicine, School of Medicine, University of Tokushima, Japan.

The basal level of plasma immunoreactive glucagon-like peptide-1 (IR GLP-1) was significantly elevated in non-insulin-dependent diabetics (NIDD), and this elevation of IR GLP-1 was mainly due to an increase in the large component of IR GLP-1, corresponding to the pancreatic form. During the oral glucose-tolerance test (OGTT), the total plasma IR GLP-1 decreased in normal subjects but increased significantly in diabetic patients. Chromatographic analysis showed that IR GLP-1 consisted of several different molecular forms. OGTT caused a decrease in the pancreatic form but increased the intestinal form in normal subject, resulting into a net decrease in total plasma IR GLP-1. Whereas in NIDD the increase in the intestinal form was more prominent and the suppression of the pancreatic form was practically abolished to result in a net increase of total plasma IR GLP-1. This observation is consistent with the fact that in normal subjects the total change in IR GLP-1 was significantly correlated with both the total change of gut glucagon as well as that of pancreatic glucagon, but in diabetics the total change of GLP-1 only correlated to that of gut glucagon. The impaired suppression of pancreatic GLP-1 and enhanced release of intestinal GLP-1 could have some physiological importance in NIDD.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011498 Protein Precursors Precursors, Protein
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D005934 Glucagon A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511) Glucagon (1-29),Glukagon,HG-Factor,Hyperglycemic-Glycogenolytic Factor,Proglucagon (33-61),HG Factor,Hyperglycemic Glycogenolytic Factor
D005951 Glucose Tolerance Test A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg). Intravenous Glucose Tolerance,Intravenous Glucose Tolerance Test,OGTT,Oral Glucose Tolerance,Oral Glucose Tolerance Test,Glucose Tolerance Tests,Glucose Tolerance, Oral
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M Hirota, and M Hashimoto, and M Hiratsuka, and C Ohboshi, and S Yoshimoto, and M Yano, and A Mizuno, and K Shima
The metabolic response to glucagon and glucagon-(1-21)-peptide in normal subjects and non insulin dependent diabetics.
September 1986, British journal of clinical pharmacology,
M Hirota, and M Hashimoto, and M Hiratsuka, and C Ohboshi, and S Yoshimoto, and M Yano, and A Mizuno, and K Shima
Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus.
June 1997, European journal of clinical investigation,
M Hirota, and M Hashimoto, and M Hiratsuka, and C Ohboshi, and S Yoshimoto, and M Yano, and A Mizuno, and K Shima
Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients.
January 1995, Digestion,
M Hirota, and M Hashimoto, and M Hiratsuka, and C Ohboshi, and S Yoshimoto, and M Yano, and A Mizuno, and K Shima
Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus.
September 1997, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
M Hirota, and M Hashimoto, and M Hiratsuka, and C Ohboshi, and S Yoshimoto, and M Yano, and A Mizuno, and K Shima
Fasting, postprandial and postprandial plus glucagon-stimulated plasma C-peptide levels in non-insulin-dependent diabetics and in control subjects.
January 1987, Acta medica Scandinavica,
M Hirota, and M Hashimoto, and M Hiratsuka, and C Ohboshi, and S Yoshimoto, and M Yano, and A Mizuno, and K Shima
Effect of metformin on blood glucose, insulin and C-peptide responses to glucagon in non-insulin dependent diabetics.
April 1983, Il Farmaco; edizione scientifica,
M Hirota, and M Hashimoto, and M Hiratsuka, and C Ohboshi, and S Yoshimoto, and M Yano, and A Mizuno, and K Shima
Plasma immunoreactive insulin response to 100g-glucose-glucagon-tolbutamide stimulation in juvenile-onset diabetics.
April 1977, The Alabama journal of medical sciences,
M Hirota, and M Hashimoto, and M Hiratsuka, and C Ohboshi, and S Yoshimoto, and M Yano, and A Mizuno, and K Shima
Effect of dietary fibre on blood glucose, plasma immunoreactive insulin, C-peptide and GIP responses in non insulin dependent (type 2) diabetics and controls.
January 1984, Acta medica Scandinavica,
M Hirota, and M Hashimoto, and M Hiratsuka, and C Ohboshi, and S Yoshimoto, and M Yano, and A Mizuno, and K Shima
C-peptide response to glucagon in black and Indian insulin-dependent diabetics.
March 1982, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
M Hirota, and M Hashimoto, and M Hiratsuka, and C Ohboshi, and S Yoshimoto, and M Yano, and A Mizuno, and K Shima
Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes.
May 2022, Diabetes, obesity & metabolism,
Copied contents to your clipboard!